The ratio of ADSCs to HSC-progenitors in adipose tissue derived SVF may provide the key to predict the outcome of stem-cell therapy

Clinical and Translational Medicine

Table 3 List of 13 ADE-MSCs-treated patient’s gender, age, medical indication, delivery methods and benefit index

Patient number	Gender: F/M	Age	Medical indication	Total number of ADE-MSCs injected (× 10⁶)	Delivery method	Benefit index
59	M	84	Parkinson	40	IV	3
60	F	57	ALS	100	IV	2
61	F	41	MS	10	Ommaya: 4 M IV: 6 M	2
62	M	92	Stroke	80	IV	4
63	F	55	MS	135	Ommaya: 60 M IV:75 M	2
64	M	94	Neuropathy	40	IV	5
65	M	66	Peyronie’s	26	Penile injection	4
66	M	80	Cardiac	10	IV	3
67	F	82	Wellness/lyme disease	30	IV	4
68	M	12	Anoxic brain injury	20	IV	4
69	M	74	Parkinson	30	IV	4
70	M	69	Erectile dysfunction	10	Penile injection	1
71	F	57	ALS	100	IV	2